An increase in galectin-3 causes cellular unresponsiveness to IFN-γ-induced signal transduction and growth inhibition in gastric cancer cells

Oncotarget

Volumn 7, Issue 12, 2016, Pages 15150-15160

  Tseng, Po Chun ^a   Chen, Chia Ling ^b   Shan, Yan Shen ^a   Lin, Chiou Feng ^c,d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

AKT; Galectin 3; GSK 3 ; IFN ; SHP2

Indexed keywords

BETA GALACTOSIDASE; CISPLATIN; GALECTIN 3; GAMMA INTERFERON; GLYCOGEN SYNTHASE KINASE 3BETA; INTERFERON REGULATORY FACTOR 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; THREONINE; ANTIVIRUS AGENT; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; STOMACH TUMOR; TUMOR CELL CULTURE;

ANTIVIRAL AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; INTERFERON-GAMMA; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84962809818     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7750     Document Type: Article

References (52)

1. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK and Sung JJ. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008; 9:279-287.
2. Brenner H, Rothenbacher D and Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009; 472:467-477.
3. Resende C, Ristimaki A and Machado JC. Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter. 2010; 15:34-39.
4. Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol. 2006; 12:192-198.
5. Katoh M. Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer. Cancer Biol Ther. 2007; 6:832-839.
6. Klein G. Cancer, apoptosis, and nonimmune surveillance. Cell Death Differ. 2004; 11:13-17.
7. Malmberg KJ and Ljunggren HG. Escape from immune- and nonimmune-mediated tumor surveillance. Semin Cancer Biol. 2006; 16:16-31.
8. Dumic J, Dabelic S and Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006; 1760:616-635.
9. Fortuna-Costa A, Gomes AM, Kozlowski EO, Stelling MP and Pavao MS. Extracellular galectin-3 in tumor progression and metastasis. Front Oncol. 2014; 4:138.
10. Yang RY, Hsu DK and Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A. 1996; 93:6737-6742.
11. Miyazaki J, Hokari R, Kato S, Tsuzuki Y, Kawaguchi A, Nagao S, Itoh K and Miura S. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep. 2002; 9:1307-1312.
12. Song S, Mazurek N, Liu C, Sun Y, Ding QQ, Liu K, Hung MC and Bresalier RS. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 2009; 69:1343-1349.
13. Song S, Ji B, Ramachandran V, Wang H, Hafley M, Logsdon C and Bresalier RS. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One. 2012; 7:e42699.
14. Oka N, Nakahara S, Takenaka Y, Fukumori T, Hogan V, Kanayama HO, Yanagawa T and Raz A. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res. 2005; 65:7546-7553.
15. Shalom-Feuerstein R, Cooks T, Raz A and Kloog Y. Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res. 2005; 65:7292-7300.
16. Kim SJ, Choi IJ, Cheong TC, Lee SJ, Lotan R, Park SH and Chun KH. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology. 2010; 138:1035-1045 e1031-1032.
17. Kim SJ, Shin JY, Lee KD, Bae YK, Choi IJ, Park SH and Chun KH. Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One. 2011; 6:e25103.
18. Kim SJ, Shin JY, Cheong TC, Choi IJ, Lee YS, Park SH and Chun KH. Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of beta-catenin in gastric cancer. Clin Exp Metastasis. 2011; 28:743-750.
19. Terabe M and Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res. 2008; 101:277-348.
20. Artis D and Spits H. The biology of innate lymphoid cells. Nature. 2015; 517:293-301.
21. Boehm U, Klamp T, Groot M and Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997; 15:749-795.
22. Parmar S and Platanias LC. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol. 2003; 15:431-439.
23. Schroder K, Hertzog PJ, Ravasi T and Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004; 75:163-189.
24. Street SE, Cretney E and Smyth MJ. Perforin and interferon- gamma activities independently control tumor initiation, growth, and metastasis. Blood. 2001; 97:192-197.
25. Pulaski BA, Smyth MJ and Ostrand-Rosenberg S. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res. 2002; 62:4406-4412.
26. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J and Yin Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med. 2003; 198:433-442.
27. Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K and Aikou T. HLA-class I expression in gastric cancer. J Surg Oncol. 2008; 97:605-608.
28. Yoshii M, Tanaka H, Ohira M, Muguruma K, Sakurai K, Kubo N, Yashiro M, Sawada T and Hirakawa K. Association of MHC class I expression and lymph node metastasis of gastric carcinoma. Hepatogastroenterology. 2013; 60:611-615.
29. Abril E, Mendez RE, Garcia A, Serrano A, Cabrera T, Garrido F and Ruiz-Cabello F. Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon. Tissue Antigens. 1996; 47:391-398.
30. Abril E, Real LM, Serrano A, Jimenez P, Garcia A, Canton J, Trigo I, Garrido F and Ruiz-Cabello F. Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol Immunother. 1998; 47:113-120.
31. Shuai K and Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003; 3:900-911.
32. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005; 5:375-386.
33. You M, Yu DH and Feng GS. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol. 1999; 19:2416-2424.
34. Tsai CC, Kai JI, Huang WC, Wang CY, Wang Y, Chen CL, Fang YT, Lin YS, Anderson R, Chen SH, Tsao CW and Lin CF. Glycogen synthase kinase-3beta facilitates IFN-gamma-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2. J Immunol. 2009; 183:856-864.
35. Tseng PC, Huang WC, Chen CL, Sheu BS, Shan YS, Tsai CC, Wang CY, Chen SO, Hsieh CY and Lin CF. Regulation of SHP2 by PTEN/AKT/GSK-3beta signaling facilitates IFN-gamma resistance in hyperproliferating gastric cancer. Immunobiology. 2012; 217:926-934.
36. Cheng YL, Huang WC, Chen CL, Tsai CC, Wang CY, Chiu WH, Chen YL, Lin YS, Chang CF and Lin CF. Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun. 2011; 412:334-340.
37. Chen SS, Sun LW, Brickner H and Sun PQ. Downregulating galectin-3 inhibits proinflammatory cytokine production by human monocyte-derived dendritic cells via RNA interference. Cell Immunol. 2015; 294:44-53.
38. Baldus SE, Zirbes TK, Weingarten M, Fromm S, Glossmann J, Hanisch FG, Monig SP, Schroder W, Flucke U, Thiele J, Holscher AH and Dienes HP. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol. 2000; 21:258-266.
39. Gollob JA, Sciambi CJ, Huang Z and Dressman HK. Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. Cancer Res. 2005; 65:8869-8877.
40. Jeon SB, Yoon HJ, Chang CY, Koh HS, Jeon SH and Park EJ. Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J Immunol. 2010; 185:7037-7046.
41. Raimond J, Rouleux F, Monsigny M and Legrand A. The second intron of the human galectin-3 gene has a strong promoter activity down-regulated by p53. FEBS Lett. 1995; 363:165-169.
42. Gaudin JC, Arar C, Monsigny M and Legrand A. Modulation of the expression of the rabbit galectin-3 gene by p53 and c-Ha-ras proteins and PMA. Glycobiology. 1997; 7:1089-1098.
43. Tseng PC, Chen CL, Shan YS, Chang WT, Liu HS, Hong TM, Hsieh CY, Lin SH and Lin CF. An increase in integrin-linked kinase non-canonically confers NF- inverted question markB-mediated growth advantages to gastric cancer cells by activating ERK1/2. Cell Commun Signal. 2014; 12:69.
44. Liu FT, Patterson RJ and Wang JL. Intracellular functions of galectins. Biochim Biophys Acta. 2002; 1572:263-273.
45. Mendonca DF, Chammas R, Liu FT, Nonogaki S, Cardoso SV, Loyola AM and de Faria PR. The inactive form of glycogen synthase kinase-3beta is associated with the development of carcinomas in galectin-3 wild-type mice, but not in galectin-3-deficient mice. Int J Clin Exp Pathol. 2012; 5:547-554.
46. Elad-Sfadia G, Haklai R, Balan E and Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem. 2004; 279:34922-34930.
47. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 2004; 4:688-694.
48. Chan RJ and Feng GS. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood. 2007; 109:862-867.
49. Chan G, Kalaitzidis D and Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008; 27:179-192.
50. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ and Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410:1107-1111.
51. Miller CH, Maher SG and Young HA. Clinical Use of Interferon-gamma. Ann N Y Acad Sci. 2009; 1182:69-79.
52. Chang YP, Tsai CC, Huang WC, Wang CY, Chen CL, Lin YS, Kai JI, Hsieh CY, Cheng YL, Choi PC, Chen SH, Chang SP, Liu HS and Lin CF. Autophagy facilitates IFN-gamma-induced Jak2-STAT1 activation and cellular inflammation. J Biol Chem. 2010; 285:28715-28722.